Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Ana Iglesias Pérez"'
Autor:
José Antonio Boga, Jonathan Fernández-Suárez, Ana Iglesias Pérez, Noelia Moran, Luis Casado, Candela Menendez, Mercedes Rodríguez-Pérez, Azucena Rodríguez-Guardado, María Martínez-Sela, Alicia García-Pérez, Sagrario Santos
Publikováno v:
Am J Trop Med Hyg
The female immigrant population is especially vulnerable to imported diseases. We describe the results of a prospective screening program for imported diseases performed in immigrant female patients. The protocol included tests for HIV, hepatitis B v
Autor:
Valentín García-Gutiérrez, Nuria Hernán, José María Guinea, Luis Felipe Casado-Montero, Gloria González, Fernando Ortega Rivas, Ana Sebrango, Angel Ramirez Payer, Miguel Piris-Villaespesa, Juan Luis Steegmann, M.A. Fernandez, Juan Carlos Hernández-Boluda, Esperanza Romero, Dragana Milojkovic, Guillermo Ortí, Sandra Valencia, Guiomar Bautista Carrascosa, Beatriz Cuevas Ruiz, Jose Manuel Puerta, Isabel Mata Vázquez, A García, Elena Amustio Díez, María-José Ramírez, Ana Iglesias Pérez, Alejandra Martínez-Trillos, Josep Maria Martí Martí-Tutusaus, José Tallón, Simone Claudiani, Concepción Boqué, Pilar Giraldo, Natalia De Las Heras Rodríguez, Angeles Portero, Maria Luisa Martin Mateos, Ana Rosell, Antonio Jiménez-Velasco, Rolando Vallansot, Jose Luis Lopez Lorenzo, Maria del Carmen García Garay, Alicia Senín, Andres Romo, Silvanna Saavedra Saavedra
Publikováno v:
ANNALS OF HEMATOLOGY
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Bosutinib is a second-generation tyrosine kinase inhibitor (2GTKI) approved at 400 mg once daily (QD) as first-line therapy in patients with chronic myeloid leukemia (CML) patients and at 500 mg QD in patients who are resistant to or intolerant of pr
Autor:
Angeles Fernandez, Juan Luis Steegmann, Andrés Romo Collado, Isabel Mata, José Tallón, María José Sánchez, Ana Iglesias Pérez, Concepción Ruiz, Ana Sebrango, Jose Luis Lopez Lorenzo, Maria del Carmen García Garay, Alejandra Martínez-Trillos, Esperanza Romero, Fernando Ortega, Maria Luisa Martin Mateos, Beatriz Cuevas, Angeles Portero, José María Guinea, Valentín García-Gutiérrez, Begoña Maestro, Sandra Valencia, Pilar Giraldo, Natalia de las Heras, Sabela Bobillo, Guillermo Deben, Concepción Boqué, Alberto Alvarez-Larrán, Guiomar Bautista
Publikováno v:
American Journal of Hematology. 90:429-433
The role of bosutinib as rescue treatment of Philadelphia chromosome-positive chronic myeloid leukemia (CML) patients after failing three previous tyrosine kinase inhibitors (TKIs) is currently unknown. We report here the largest series (to our knowl
Autor:
Valentín, García-Gutiérrez, Alejandra, Martinez-Trillos, Jose Luis, Lopez Lorenzo, Guiomar, Bautista, Maria Luisa, Martin Mateos, Alberto, Alvarez-Larrán, Ana, Iglesias Pérez, Andrés, Romo Collado, Angeles, Fernandez, Angeles, Portero, Beatriz, Cuevas, Concepción, Ruiz, Esperanza, Romero, Fernando, Ortega, Isabel, Mata, José, Tallón, Maria Del Carmen, García Garay, María José, Ramirez Sánchez, Natalia, de Las Heras, Pilar, Giraldo, Sabela, Bobillo, José María, Guinea, Guillermo, Deben, Sandra, Valencia, Ana, Sebrango, Concepción, Boqué, Begoña, Maestro, Juan Luis, Steegmann
Publikováno v:
American journal of hematology. 90(5)
The role of bosutinib as rescue treatment of Philadelphia chromosome-positive chronic myeloid leukemia (CML) patients after failing three previous tyrosine kinase inhibitors (TKIs) is currently unknown. We report here the largest series (to our knowl
Autor:
Concepción Boqué, María José Sánchez, Valentín García-Gutiérrez, Jose Manuel Puerta, Antonio J. Jiménez, Isabel Mata Vázquez, Ana Isabel Rosell Mas, A García, Esperanza Romero Picos, Alberto Alvarez Larran, Maria del Carmen García Garay, Gloria González, Pilar Giraldo, Simone Claudiani, Elena Amutio Díez, Fernando Ortega Rivas, Silvana Saavedra Gerosa, Dragana Milojkovic, Beatriz Cuevas Ruiz, Guiomar Bautista Carrascosa, Mª Ángeles Fernández Fernández, Sabela Bobillo Varela, Sandra Valencia, José Tallón Pérez, Jose María Guinea de Castro, Mario Andrés Romo Collada, Josep Maria Martí Tutusaus, Alejandra Martinez Trillos, Juan Luis Steegmann, Luis Felipe Casado, Angel Ramirez Payer, Ana Sebrango Sadia, Natalia De Las Heras Rodríguez, Ana Iglesias Pérez, Maria Luisa Martin Mateos, Nuria Hernanz Soler, Rolando Vallansot, Jose Luis Lopez Lorenzo
Publikováno v:
Blood. 126:2786-2786
BACKGROUND: Despite the excellent prognostic of chronic myeloid leukemia (CML) patients since the introduction of tyrosine kinase inhibitors (TKIs), approximately 50% of patients that are treated with TKIs will discontinue first line treatment due to
Autor:
Maria del Carmen García Garay, Concepción Ruiz, Alejandra Martinez-Trillo, Andrés Romo Collado, Ana Iglesias Pérez, María José Sánchez, Isabel Mata, Jose Luis Lopez Lorenzo, Guiomar Bautista, Juan Luis Steegmann, Beatriz Cuevas, Ana Sebrango, Alberto Alvarez, Guillermo Deben, Fernando Ortega, Esperanza Romero, Concepción Boqué, Maria Luisa Martin Mateos, Sandra Valencia, Angeles Fernandez, Angeles Portero, Pilar Giraldo, Sabela Bobillo, Natalia de las Heras, José Tallón, José María Guinea, Valentín García-Gutiérrez, Begoña Maestro
Publikováno v:
Blood. 124:5523-5523
Second-generation TKIs have demonstrated efficacy and an acceptable tolerability in patients (pts) with chronic myeloid leukemia (CML); however, new data from so called “off target” side effects have been published. For example, serious concerns